Clinicopathologic Analysis of PD-L1 and PD-L2 Expression in Renal Cell Carcinoma: Association with Oncogenic Proteins Status

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer et al. · New England Journal of Medicine · 2012 · 12.7K citations · Full text

Life Sciences, Immunology, Oncology +17

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow et al. · New England Journal of Medicine · 2012 · 8K citations · Full text

Life Sciences, Immunology, Oncology +17

Tumor-associated B7-H1 promotes T-cell apoptosis: A potential mechanism of immune evasion

Haidong Dong, Scott E. Strome, Diva R. Salomão et al. · Nature Medicine · 2002 · 5K citations

Life Sciences, Immunology, Oncology +17

Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial

Cora N. Sternberg, Ian D. Davis, Jozef Mardiak et al. · Journal of Clinical Oncology · 2010 · 2.5K citations · Full text

Medicine, Oncology, Pharmacology +17

PD-L1 is a novel direct target of HIF-1α, and its blockade under hypoxia enhanced MDSC-mediated T cell activation

Muhammad Zaeem Noman, Giacomo Desantis, Bassam Janji et al. · The Journal of Experimental Medicine · 2014 · 2.1K citations · Full text

Medicine, Immunology, Oncology +16